Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
Key claim: Intermittent dasatinib plus quercetin senolytic therapy improved liver fibrosis by ≥1 stage without MASH worsening in 47% of participants versus 7% on placebo, and resolved MASH more often, in a phase-2 randomized trial of fibrotic MASH.
Abstract
Cellular senescence plays an important role in hepatic inflammation and fibrosis. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (-1.43 ± 1.22 versus -0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 .
Why this matters
Until now, the dasatinib+quercetin senolytic case rested almost entirely on mouse models and uncontrolled small human pilots; this is the first randomized, placebo-controlled trial to show a hard tissue endpoint (paired-biopsy fibrosis regression) in a defined disease population, with molecular confirmation that senescent and fibrogenic cell populations declined. It moves D+Q from a preclinical/biohack narrative toward a drug-development track in MASH, while leaving open whether the biopsy signal translates to clinical outcomes, generalizes beyond MASH, or scales safely with repeated intermittent dosing.